中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
23期
94-95
,共2页
多发性硬化%复发缓解型%干扰素-β%功能缺损状况评分%复发率
多髮性硬化%複髮緩解型%榦擾素-β%功能缺損狀況評分%複髮率
다발성경화%복발완해형%간우소-β%공능결손상황평분%복발솔
MS%RRMS%IFN-β%EDSS%The recurrence rate
目的：探讨不同剂量的干扰素-β(IFN-β)治疗多发性硬化(MS)的效果。方法整群选取2012年3月—2014年3月入医院治疗的复发缓解型多发性硬化(RRMS)患者76例作为研究对象,根据用药剂量将患者分为大剂量组和小剂量组,大剂量组(38例)予以干扰素-β-1b(IFN-β1b)250μg行皮下注射,2 d用药1次；小剂量组(38例)予以IFN-β1b50μg行肌肉注射,2 d用药1次；行扩展残疾状况评分(EDSS),记录两组不良用药反应,随访6个月记录两组复发率、持续进展发生率。结果大剂量组局部注射部位疼痛、局部瘙痒的发生几率为39.47%、34.21%明显高于小剂量组15.79%、10.53%,差异具有统计学意义(P<0.05),不良反应在可耐受范围内；治疗48周大剂量组复发率和持续进展率分别为36.84%、18.42%均显著低于小剂量组,差异具有统计学意义(P<0.05)。结论大剂量IFN-β1b能够降低RRMS患者的疾病复发率和持续进展率,不良反应相对较多,但均在可耐受范围内。
目的：探討不同劑量的榦擾素-β(IFN-β)治療多髮性硬化(MS)的效果。方法整群選取2012年3月—2014年3月入醫院治療的複髮緩解型多髮性硬化(RRMS)患者76例作為研究對象,根據用藥劑量將患者分為大劑量組和小劑量組,大劑量組(38例)予以榦擾素-β-1b(IFN-β1b)250μg行皮下註射,2 d用藥1次；小劑量組(38例)予以IFN-β1b50μg行肌肉註射,2 d用藥1次；行擴展殘疾狀況評分(EDSS),記錄兩組不良用藥反應,隨訪6箇月記錄兩組複髮率、持續進展髮生率。結果大劑量組跼部註射部位疼痛、跼部瘙癢的髮生幾率為39.47%、34.21%明顯高于小劑量組15.79%、10.53%,差異具有統計學意義(P<0.05),不良反應在可耐受範圍內；治療48週大劑量組複髮率和持續進展率分彆為36.84%、18.42%均顯著低于小劑量組,差異具有統計學意義(P<0.05)。結論大劑量IFN-β1b能夠降低RRMS患者的疾病複髮率和持續進展率,不良反應相對較多,但均在可耐受範圍內。
목적：탐토불동제량적간우소-β(IFN-β)치료다발성경화(MS)적효과。방법정군선취2012년3월—2014년3월입의원치료적복발완해형다발성경화(RRMS)환자76례작위연구대상,근거용약제량장환자분위대제량조화소제량조,대제량조(38례)여이간우소-β-1b(IFN-β1b)250μg행피하주사,2 d용약1차；소제량조(38례)여이IFN-β1b50μg행기육주사,2 d용약1차；행확전잔질상황평분(EDSS),기록량조불량용약반응,수방6개월기록량조복발솔、지속진전발생솔。결과대제량조국부주사부위동통、국부소양적발생궤솔위39.47%、34.21%명현고우소제량조15.79%、10.53%,차이구유통계학의의(P<0.05),불량반응재가내수범위내；치료48주대제량조복발솔화지속진전솔분별위36.84%、18.42%균현저저우소제량조,차이구유통계학의의(P<0.05)。결론대제량IFN-β1b능구강저RRMS환자적질병복발솔화지속진전솔,불량반응상대교다,단균재가내수범위내。
Objective To investigate the effect of different doses of interferon beta (IFN-beta) in the treatment of multiple sclero-sis (MS). Methods 76 patients were selected which were treated for relapse remitting multiple sclerosis (RRMS) in our hospital during March 2012 to March 2014 as the research object. According to the dosage, the patients were divided into large dose group and small dose group, large dose group with 38 cases received interferon-β-1b (IFN-β1b)250μg for subcutaneous injection once every two days, while small dose group with 38 cases received IFN-β1b 50μg for intramuscular injection once every 2 days. The expanded disability status score (EDSS) recorded two groups of adverse drug reaction, and followed up for 6 months to record the recurrence rate and the incidence rate of sustained progress. Results The large dose incidence rate of local injection site pain and local itching was 39.47%and 34.21%which was significantly higher than small dose group which were 15.79%and 10.53%. The difference was statistically significant (P<0.05). Adverse reactions were in the tolerance range. During the 48 weeks of treatment, the recurrence rate and the incidence rate of sustained progress of large dose group respectively were 36.84% and 18.42% which were significantly lower than small dose group. The difference was significant (P<0.05). Conclusion Large dose of IFN-β1b can re-duce the recurrence rate and the incidence rate of sustained progress of patients with RRMS. Though adverse reactions are rela-tively high, but are in the range of tolerance.
